Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Axolabs, Mirrx, TriPhos, and More


Title: Alternative Export Pathways for Vector-expressed RNA Interference

Patent Number: 8,691,567

Filed: June 21, 2012

Lead Inventor: Scott Harper, University of Iowa

Title: Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds

Patent Number: 8,691,750

Filed: May 8, 2012

Lead Inventor: Rainer Constien, Axolabs

Title: Compositions for Treating Respiratory Viral Infections and Their Use

Patent Number: 8,691,781

Filed: June 1, 2007

Lead Inventor: Qingquan Tang, Sirnaomics

Title: Compositions and Methods for Non-parenteral Delivery of Oligonucleotides

Patent Number: 8,691,785

Filed: Jan. 7, 2013

Lead Inventor: Ching-Leou Teng, Isis Pharmaceuticals

Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-stranded RNA

Patent Number: 8,691,786

Filed: Jan. 24, 2013

Lead Inventor: John Rossi, City of Hope

Title: Delivering Functional Nucleic Acids to Mammalian Cells via Bacterially Derived, Intact Minicells

Patent Number: 8,691,963

Filed: Aug. 25, 2005

Lead Inventor: Himanshu Brahmbhatt, Engeneic Molecular Delivery

Title: Oligonucleotides for Modulating Target RNA Activity

Patent Number: 8,691,965

Filed: June 13, 2008

Inventor: Thorleif Moller, Mirrx Therapeutics

Title: Multiple Promoter Expression Cassettes for Simultaneous Delivery of RNAi Agents

Patent Number: 8,691,967

Filed: Sept. 26, 2012

Lead Inventor: Petrus Roelvink, Benitec

Title: Self-delivering Bio-labile Phosphate Pro-oligos for Oligonucleotide-based Therapeutics and Mediating RNA Interference

Patent Number: 8,691,971

Filed: Sept. 23, 2009

Inventor: Scott Petersen, Traversa Therapeutics (TriPhos Therapeutics)

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.